Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists.

Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, McWhirter SM, Raulet DH.

Sci Immunol. 2020 Mar 20;5(45). pii: eaaz2738. doi: 10.1126/sciimmunol.aaz2738.

PMID:
32198222
2.

Author Correction: SLC19A1 transports immunoreactive cyclic dinucleotides.

Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH.

Nature. 2020 Mar;579(7800):E12. doi: 10.1038/s41586-020-2064-8.

PMID:
32144410
3.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2019 Oct 15;29(3):785-789. doi: 10.1016/j.celrep.2019.09.089. No abstract available.

4.

SLC19A1 transports immunoreactive cyclic dinucleotides.

Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH.

Nature. 2019 Sep;573(7774):434-438. doi: 10.1038/s41586-019-1553-0. Epub 2019 Sep 11. Erratum in: Nature. 2020 Mar;579(7800):E12.

5.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047. Erratum in: Cell Rep. 2019 Oct 15;29(3):785-789.

6.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857.

7.

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.

Van Dis E, Sogi KM, Rae CS, Sivick KE, Surh NH, Leong ML, Kanne DB, Metchette K, Leong JJ, Bruml JR, Chen V, Heydari K, Cadieux N, Evans T, McWhirter SM, Dubensky TW Jr, Portnoy DA, Stanley SA.

Cell Rep. 2018 May 1;23(5):1435-1447. doi: 10.1016/j.celrep.2018.04.003.

8.

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

9.

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele".

Sivick KE, Surh NH, Desbien AL, Grewal EP, Katibah GE, McWhirter SM, Dubensky TW Jr.

J Immunol. 2017 Jun 1;198(11):4183-4185. doi: 10.4049/jimmunol.1700294. No abstract available.

10.

The host STING pathway at the interface of cancer and immunity.

Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892. Epub 2016 Jul 1. Review.

11.

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Immunol. 2016 Apr 1;196(7):3191-8. doi: 10.4049/jimmunol.1502538. Epub 2016 Feb 29.

12.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF.

Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.

13.

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr, Kim Y.

Sci Transl Med. 2015 Apr 15;7(283):283ra52. doi: 10.1126/scitranslmed.aaa4306.

14.

Gfi1 and gfi1b repress rag transcription in plasmacytoid dendritic cells in vitro.

Chow KT, Schulz D, McWhirter SM, Schlissel MS.

PLoS One. 2013 Sep 24;8(9):e75891. doi: 10.1371/journal.pone.0075891. eCollection 2013.

15.

MK5 activates Rag transcription via Foxo1 in developing B cells.

Chow KT, Timblin GA, McWhirter SM, Schlissel MS.

J Exp Med. 2013 Jul 29;210(8):1621-34. doi: 10.1084/jem.20130498. Epub 2013 Jul 22.

16.

Gfi1b negatively regulates Rag expression directly and via the repression of FoxO1.

Schulz D, Vassen L, Chow KT, McWhirter SM, Amin RH, Möröy T, Schlissel MS.

J Exp Med. 2012 Jan 16;209(1):187-99. doi: 10.1084/jem.20110645. Epub 2011 Dec 26.

17.

Induction of type I interferons by bacteria.

Monroe KM, McWhirter SM, Vance RE.

Cell Microbiol. 2010 Jul;12(7):881-90. doi: 10.1111/j.1462-5822.2010.01478.x. Epub 2010 May 6. Review.

18.

Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.

Wilson MK, McWhirter SM, Amin RH, Huang D, Schlissel MS.

Mol Cells. 2010 Apr;29(4):333-41. doi: 10.1007/s10059-010-0029-8. Epub 2010 Mar 4.

19.

Identification of host cytosolic sensors and bacterial factors regulating the type I interferon response to Legionella pneumophila.

Monroe KM, McWhirter SM, Vance RE.

PLoS Pathog. 2009 Nov;5(11):e1000665. doi: 10.1371/journal.ppat.1000665. Epub 2009 Nov 20.

20.

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP.

McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, Ishii KJ, Akira S, Colonna M, Chen ZJ, Fitzgerald KA, Hayakawa Y, Vance RE.

J Exp Med. 2009 Aug 31;206(9):1899-911. doi: 10.1084/jem.20082874. Epub 2009 Aug 3.

21.

Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch.

Panne D, McWhirter SM, Maniatis T, Harrison SC.

J Biol Chem. 2007 Aug 3;282(31):22816-22. Epub 2007 May 25.

22.

Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity.

Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T.

Science. 2007 Mar 2;315(5816):1274-8.

23.

Connecting mitochondria and innate immunity.

McWhirter SM, Tenoever BR, Maniatis T.

Cell. 2005 Sep 9;122(5):645-7. Review.

24.

IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts.

McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T.

Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):233-8. Epub 2003 Dec 16.

25.

IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T.

Nat Immunol. 2003 May;4(5):491-6.

PMID:
12692549
26.

Human adenovirus proteinase: DNA binding and stimulation of proteinase activity by DNA.

McGrath WJ, Baniecki ML, Li C, McWhirter SM, Brown MT, Toledo DL, Mangel WF.

Biochemistry. 2001 Nov 6;40(44):13237-45.

PMID:
11683632
27.

Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc.

Baniecki ML, McGrath WJ, McWhirter SM, Li C, Toledo DL, Pellicena P, Barnard DL, Thorn KS, Mangel WF.

Biochemistry. 2001 Oct 16;40(41):12349-56. Erratum in: Biochemistry 2002 Jan 8;41(1):430.

28.

Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.

McWhirter SM, Pullen SS, Werneburg BG, Labadia ME, Ingraham RH, Crute JJ, Kehry MR, Alber T.

Cold Spring Harb Symp Quant Biol. 1999;64:551-62. Review. No abstract available.

PMID:
11232332
29.

High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR.

Biochemistry. 1999 Aug 3;38(31):10168-77.

PMID:
10433725
30.

Crystallographic analysis of CD40 recognition and signaling by human TRAF2.

McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8408-13.

31.

The Cap-binding protein eIF4E promotes folding of a functional domain of yeast translation initiation factor eIF4G1.

Hershey PE, McWhirter SM, Gross JD, Wagner G, Alber T, Sachs AB.

J Biol Chem. 1999 Jul 23;274(30):21297-304.

Supplemental Content

Loading ...
Support Center